参考文献

2020-09-01

1: Theilen TM, Soerensen J, Bochennek K, Becker M, Schwabe D, Rolle U, Klingebiel T, Lehrnbecher T. Crizotinib in ALK(+) inflammatory myofibroblastic tumors-Current experience and future perspectives. Pediatr Blood Cancer. 2017 Dec 29. doi: 10.1002/pbc.26920. [Epub ahead of print] Review. PubMed PMID: 29286567.

2: Sgambato A, Casaluce F, Maione P, Gridelli C. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 2018 Jan;18(1):71-80. doi: 10.1080/14737140.2018.1412260. Epub 2017 Dec 6. Review. PubMed PMID: 29187012.

3: Manicone M, Scaini MC, Rodriquenz MG, Facchinetti A, Tartarone A, Aieta M, Zamarchi R, Rossi E. Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. J Thorac Dis. 2017 Oct;9(Suppl 13):S1391-S1396. doi: 10.21037/jtd.2017.08.151. Review. PubMed PMID: 29184678; PubMed Central PMCID: PMC5676101.

4: Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature. Clin Lung Cancer. 2017 Oct 28. pii: S1525-7304(17)30302-9. doi: 10.1016/j.cllc.2017.10.008. [Epub ahead of print] Review. PubMed PMID: 29174221.

5: Institute for Quality and Efficiency in Health Care. Ceritinib -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Sep 29. Available from http://www.ncbi.nlm.nih.gov/books/NBK458396/ PubMed PMID: 29144697.

6: Institute for Quality and Efficiency in Health Care. Crizotinib (New Therapeutic Indication) -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2016 Mar 30. Available from http://www.ncbi.nlm.nih.gov/books/NBK458423/ PubMed PMID: 29144683.

7: Alshareef A. Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers. Cancers (Basel). 2017 Oct 28;9(11). pii: E148. doi: 10.3390/cancers9110148. Review. PubMed PMID: 29143801; PubMed Central PMCID: PMC5704166.

8: Passaro A, Prelaj A, Pochesci A, Spitaleri G, Rossi G, Del Signore E, Catania C, de Marinis F. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients. Drugs Today (Barc). 2017 Aug;53(8):435-446. doi: 10.1358/dot.2017.53.8.2676119. Review. PubMed PMID: 29119148.

9: Jain RK, Chen H. Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib. Lung Cancer (Auckl). 2017 Oct 13;8:169-177. doi: 10.2147/LCTT.S126507. eCollection 2017. Review. PubMed PMID: 29075144; PubMed Central PMCID: PMC5648304.

10: Mo HN, Liu P. Targeting MET in cancer therapy. Chronic Dis Transl Med. 2017 Jul 19;3(3):148-153. doi: 10.1016/j.cdtm.2017.06.002. eCollection 2017 Sep. Review. PubMed PMID: 29063069; PubMed Central PMCID: PMC5643781.

11: Boromand N, Hasanzadeh M, ShahidSales S, Farazestanian M, Gharib M, Fiuji H, Behboodi N, Ghobadi N, Hassanian SM, Ferns GA, Avan A. Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer. J Cell Physiol. 2017 Oct 23. doi: 10.1002/jcp.26232. [Epub ahead of print] Review. PubMed PMID: 29058790.

12: Muller IB, de Langen AJ, Giovannetti E, Peters GJ. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. Onco Targets Ther. 2017 Sep 13;10:4535-4541. doi: 10.2147/OTT.S109493. eCollection 2017. Review. PubMed PMID: 28979145; PubMed Central PMCID: PMC5602476.

13: Pal P, Khan Z. ROS1-1. J Clin Pathol. 2017 Dec;70(12):1001-1009. doi: 10.1136/jclinpath-2016-204244. Epub 2017 Sep 13. Review. PubMed PMID: 28903995.

14: Cao S, Nambudiri VE. Anaplastic Lymphoma Kinase in Cutaneous Malignancies. Cancers (Basel). 2017 Sep 12;9(9). pii: E123. doi: 10.3390/cancers9090123. Review. PubMed PMID: 28895885; PubMed Central PMCID: PMC5615338.

15: Califano R, Greystoke A, Lal R, Thompson J, Popat S. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. Lung Cancer. 2017 Sep;111:51-58. doi: 10.1016/j.lungcan.2017.06.004. Epub 2017 Jun 9. Review. PubMed PMID: 28838397.

16: Lin JJ, Shaw AT. Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol. 2017 Nov;12(11):1611-1625. doi: 10.1016/j.jtho.2017.08.002. Epub 2017 Aug 14. Review. PubMed PMID: 28818606; PubMed Central PMCID: PMC5659942.

17: Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Des Devel Ther. 2017 Jul 5;11:2047-2063. doi: 10.2147/DDDT.S113500. eCollection 2017. Review. PubMed PMID: 28740365; PubMed Central PMCID: PMC5503498.

18: Losanno T, Gridelli C. Recent advances in targeted advanced lung cancer therapy in the elderly. Expert Rev Anticancer Ther. 2017 Sep;17(9):787-797. doi: 10.1080/14737140.2017.1348232. Epub 2017 Jul 4. Review. PubMed PMID: 28656792.

19: Institute for Quality and Efficiency in Health Care. Addendum to Commission A12-15 (Crizotinib) [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Apr 15. Available from http://www.ncbi.nlm.nih.gov/books/NBK385688/ PubMed PMID: 28609038.

20: Institute for Quality and Efficiency in Health Care. Crizotinib -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Feb 13. Available from http://www.ncbi.nlm.nih.gov/books/NBK385642/ PubMed PMID: 28609030.